Effects of pioglitazone on coronary atherosclerotic plaques of patients with impaired glucose tolerance or type 2 diabetes mellitus:a randomized,open rabelled,prospective study.

Effects of pioglitazone on coronary atherosclerotic plaques of patients with impaired glucose tolerance or type 2 diabetes mellitus:a randomized,open rabelled,prospective study. - Effects of pioglitazone on coronary atherosclerotic plaques:a randomized,open rabelled,prospective study of Pioglitazone Intervention on Coronary Atherosclerosis (PIGEON) using intravascular ultrasound.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-C000000230

Enrollment

Registered

2005-12-01

Start date

2003-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Impaired glucose tolerance or type 2 diabetes mellitus with coronary artery disease

Interventions

Intervention group:Start to take pioglitazone 15mg per day after percutaneous coronary angioplasty and increase a dose to 30mg per day at 14days after angioplasty.And continue in 6 months. Control g

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patient who have impaired glucose tolerance or type 2 diabetes mellitus with undergoing percutaneous coronary angioplasty.

Exclusion criteria

Exclusion criteria: Heart failure,acute myocardial infarction,severe hepatic or renal dysfunction,to take insulin,already to take pioglitazone,episode of adverse effect by troglitazone,pregnancy and severe hypercholesterolemia.

Design outcomes

Primary

Measure	Time frame
Plaque volume,vessel volume,lumen volume and radiofrquency data assessed with intravascular ultrasound. Plasma glucose,HbA1C,insulin,total cholesterol,triglyceride,LDL,HDL,MDA-LDL,8-isoprostane,MMP-9,MCP-1,PAI-1,TNF-a and hsCRP. Major adverse cardiovascular event and harmful effect of pioglitazone	—

Secondary

Measure	Time frame
Plasma GOT,GPT,T-BIL,CPK,ALP,G-GTP and LDH	—

Countries

Japan

Contacts

Public ContactTakashi Nakayama

Chiba University Graduate School of Medicine Division of cardiovascular science and medicine

043-222-7171

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026